Descripción general
El herpes genital es una infección de trasmisión sexual común. El virus del herpes simple provoca herpes genital. El herpes genital a menudo se propaga por contacto piel con piel durante las relaciones sexuales.
Algunas personas infectadas con el virus pueden presentar síntomas muy leves o ningún síntoma. Sin embargo, igualmente pueden contagiar el virus a otras personas. Otras personas presentan dolor, picazón y llagas alrededor de los genitales, el ano o la boca.
No existe una cura para el herpes genital. Los síntomas suelen volver a aparecer después del primer brote. Los medicamentos pueden aliviar los síntomas. También pueden reducir el riesgo de contagiar a otras personas. Usar preservativos puede ayudar a prevenir el contagio de una infección por herpes genital.
Productos y servicios
Bibliografía: Mayo Clinic Family Health Book (Libro de Salud Familiar de Mayo Clinic) 5.ª edición
Mostrar más productos de Mayo Clinic
Síntomas
Ampollas de herpes genital en un pene
Herpes genital
Agrandar la imagen
La mayoría de las personas infectadas con el virus del herpes simple no saben que lo tienen, ya que no presentan síntomas o estos son muy leves.
Los síntomas comienzan entre 2 y 12 días después de la exposición al virus. Estos son algunos síntomas posibles:
Dolor o picazón alrededor de los genitales
Pequeños bultos o ampollas alrededor de los genitales, el ano o la boca
Úlceras dolorosas que se forman cuando las ampollas se rompen y exudan o sangran
Costras que se forman a medida que las úlceras se curan
Micción dolorosa
Secreción de la uretra, el conducto que expulsa la orina del cuerpo
Secreción de la vagina
Durante el primer brote, es probable que también tengas síntomas similares a los de la gripe, como los siguientes:
Fiebre
Dolor de cabeza
Dolores en el cuerpo
Hinchazón de los ganglios linfáticos de la ingle
Diferencias en la ubicación de los síntomas
Las llagas aparecen en el lugar por donde la infección ingresa al cuerpo. La infección se puede propagar al tocarte una llaga y después frotarte o rascarte otra zona del cuerpo, como los dedos de las manos o los ojos.
Las llagas pueden aparecer en las siguientes partes del cuerpo:
Glúteos
Muslos internos
Recto
Ano
Boca
Uretra
Vulva
Vagina
Cuello del útero
Pene
Escroto
Brotes repetitivos
Después del primer brote de herpes genital, suelen volver a aparecer los síntomas (brotes o episodios recurrentes).
La frecuencia con la que suceden los brotes recurrentes varía mucho. Generalmente, presentarás la mayor cantidad de brotes durante el primer año después de la infección. Pueden aparecer menos frecuentemente con el transcurso del tiempo. Los síntomas que presentes durante los brotes recurrentes no suelen durar tanto ni ser tan graves como el primero.
Se pueden notar señales de alerta unas horas o unos días antes de que comience el nuevo brote. Estos síntomas se llaman pródromo. Entre ellos se incluyen los siguientes:
Dolor en la zona genital
Hormigueo o dolor intenso en
e632 www.thelancet.comhiv Vol 6 September 2019ViewpoiAlyciaGold776
e632 www.thelancet.com/hiv Vol 6 September 2019
Viewpoint
The disconnect between individual-level and population-level
HIV prevention benefits of antiretroviral treatment
Stefan Baral, Amrita Rao, Patrick Sullivan, Nancy Phaswana-Mafuya, Daouda Diouf, Greg Millett, Helgar Musyoki, Elvin Geng, Sharmistha Mishra
In 2019, the HIV pandemic is growing and soon over 40 million people will be living with HIV. Effective population-
based approaches to decrease HIV incidence are as relevant as ever given modest reductions observed over the past
decade. Treatment as prevention is often heralded as the path to improve HIV outcomes and to reduce HIV
incidence. Although treatment of an individual does eliminate onward transmission to serodifferent partners
(unde tectable=untransmittable or U=U), population-level observational and experimental data have not shown a similar
effect with scale-up of treatment on reducing HIV incidence. This disconnect might be the result of little attention given
to heterogeneities of HIV acquisition and transmission risks that exist in people at risk for and living with HIV, even in
the most broadly generalised epidemics. Available data suggest that HIV treatment is treatment, HIV prevention is
prevention, and specificity of HIV treatment approaches towards people at highest risk of onward transmission drives
the intersection between the two. All people living with HIV deserve HIV treatment, but both more accurately estimating
and optimising the potential HIV prevention effects of universal treatment approaches necessitates understanding who
is being supported with treatment rather than a focus on treatment targets such as 90-90-90 or 95-95-95.
Introduction
In 2019, we are at a pivotal time in the global HIV response
in that many people believe that the HIV pandemic is
over given the advances in HIV treatment.1 Yet the HIV
pandemic continues to grow as defined by numbers of
people living with HIV. Specifically, given the encouraging
decreases in overall mortality among people living with
HIV, in the context of universal treat ment as prevention,
approximately 930 000 more people annually (1·7 million
new infections minus 770 000 deaths of people living with
HIV) require anti retroviral therapy (ART) and many more
would need to change ART regimens. At the current rate
of new infections, over 40 million people will be living
with HIV by 2025.2 The global optimism about the HIV
pandemic has not been matched by decreases in new
HIV infections. New infections have declined by less than
2% per year since 2005, which means that between
1·8 and 2·5 million people acquired HIV in 2017.2,3 To
date, just over 60% of the 37·9 million people living with
HIV are on ART; of those 37·9 million, just over half
(20·1 million) are estimated to have achieved viral sup
pression.2 Taken together, these data suggest that an
estimated 18 million people living with HIV require ART
or improved ART regimens giv ...
e632 www.thelancet.comhiv Vol 6 September 2019ViewpoiAlyciaGold776
e632 www.thelancet.com/hiv Vol 6 September 2019
Viewpoint
The disconnect between individual-level and population-level
HIV prevention benefits of antiretroviral treatment
Stefan Baral, Amrita Rao, Patrick Sullivan, Nancy Phaswana-Mafuya, Daouda Diouf, Greg Millett, Helgar Musyoki, Elvin Geng, Sharmistha Mishra
In 2019, the HIV pandemic is growing and soon over 40 million people will be living with HIV. Effective population-
based approaches to decrease HIV incidence are as relevant as ever given modest reductions observed over the past
decade. Treatment as prevention is often heralded as the path to improve HIV outcomes and to reduce HIV
incidence. Although treatment of an individual does eliminate onward transmission to serodifferent partners
(unde tectable=untransmittable or U=U), population-level observational and experimental data have not shown a similar
effect with scale-up of treatment on reducing HIV incidence. This disconnect might be the result of little attention given
to heterogeneities of HIV acquisition and transmission risks that exist in people at risk for and living with HIV, even in
the most broadly generalised epidemics. Available data suggest that HIV treatment is treatment, HIV prevention is
prevention, and specificity of HIV treatment approaches towards people at highest risk of onward transmission drives
the intersection between the two. All people living with HIV deserve HIV treatment, but both more accurately estimating
and optimising the potential HIV prevention effects of universal treatment approaches necessitates understanding who
is being supported with treatment rather than a focus on treatment targets such as 90-90-90 or 95-95-95.
Introduction
In 2019, we are at a pivotal time in the global HIV response
in that many people believe that the HIV pandemic is
over given the advances in HIV treatment.1 Yet the HIV
pandemic continues to grow as defined by numbers of
people living with HIV. Specifically, given the encouraging
decreases in overall mortality among people living with
HIV, in the context of universal treat ment as prevention,
approximately 930 000 more people annually (1·7 million
new infections minus 770 000 deaths of people living with
HIV) require anti retroviral therapy (ART) and many more
would need to change ART regimens. At the current rate
of new infections, over 40 million people will be living
with HIV by 2025.2 The global optimism about the HIV
pandemic has not been matched by decreases in new
HIV infections. New infections have declined by less than
2% per year since 2005, which means that between
1·8 and 2·5 million people acquired HIV in 2017.2,3 To
date, just over 60% of the 37·9 million people living with
HIV are on ART; of those 37·9 million, just over half
(20·1 million) are estimated to have achieved viral sup
pression.2 Taken together, these data suggest that an
estimated 18 million people living with HIV require ART
or improved ART regimens giv ...
Pequeño análisis sobre la necesidad de Vacunar y su impacto en la sociedad en...Dr. Manuel Concepción
Debo vacunar a mi hijo.doc
https://xemide-new-american-institute.tumblr.com/
https://www.youtube.com/watch?v=S1zaOUV0BTg
@newaericaninstitutexcupware
https://twitter.com/grow_follow
"Brian Shilhavy"
Dr. Andrew Moulden
https://www.amazon.com/Medical-Doctors-Opposed-Forced-Vaccinations-ebook/dp/B00YVU2K0I/ref=pd_sim_351_1
http://healthimpactnews.com/2014/gardasil-vaccine-one-more-girl-dead/
Vademecum.es
Papilomavirus (tipos humanos 6, 11, 16, 18, 31, 33, 45, 52, 58)
New england latest post.
http://www.nejm.org/medical-research/viral-infections#qs=%3Fsubtopic%3Dviral-infections%26category%3Dresearch
http://www.nejm.org/doi/full/10.1056/NEJMoa1612296
SOURCE INFORMATION
From the Department of Epidemiology Research, Statens Serum Institut, Copenhagen (N.M.S., B.P., D.M.-N., H.S., A.H.); and the Clinical Epidemiology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm (B.P.).
Address reprint requests to Dr. Scheller at the Department of Epidemiology Research, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark, or a
nims@ssi.dk.
Informacion negativa técnica.
http://www.nhs.uk/Conditions/vaccinations/Pages/hpv-vaccine-cervarix-gardasil-side-effects.aspx
HPV vaccine side effects - Vaccinations - NHS Choices
Find out the side effects of the HPV vaccine and how common they are plus how to report a vaccine side effect.
nhs.uk
http://www.nhs.uk/Conditions/vaccinations/Pages/reporting-side-effects.aspx
CDC opinion on vaccine safety
https://www.cdc.gov/vaccinesafety/research/publications/index.html
Vaccine Safety Publications Publications | Research | Vaccine Safety | CDC
Access publications on vaccine safety by specific safety system, safety topic, and year.
cdc.gov
IN SPANISH
https://www.cdc.gov/vaccines/vpd-vac/hpv/downloads/dis-HPV-color-office-sp.pdf
https://www.cdc.gov/vaccines/parents/diseases/teen/hpv-indepth-color-sp.pdf
www.cdc.gov
cdc.gov
Human PapillomavirusVaccineUSU, FNP 590 Health Promotion, EdNarcisaBrandenburg70
Human Papillomavirus
Vaccine
USU, FNP 590 Health Promotion, Education, and Disease Prevention Across the Lifespan
Our Group 2 presentation is on the Human Papilloma Virus Vaccine. We will talk about what the HPV virus is, how you contact the virus and can prevent getting the virus, some information about the vaccine which includes some pros/cons and the issues and controversy surrounding it.
1
HPV is a group of approximately 150 related viruses that can lead up to 6 different types of cancers later on in life.
HPV is the most common sexually transmitted infection.
HPV appears as skin or mucous membrane growths on the vagina, cervix, rectum, anus, penis, and scrotum.
What is Human Papilloma Virus (HPV)?
HPV is spread from skin to skin sexual contact with someone who has the virus.
HPV is the most common STD. Most people do not know they have it unless they feel or see the skin irritation and see their physician for diagnosis but the lesions usually go away on their own.
How do you get HPV?
The best way to prevent contracting HPV is to avoid sexual contact with someone who has the virus.
The HPV vaccine significantly reduces your chances of contracting the virus.
Prevention of HPV
HPV vaccination
-The vaccine is recommended for children at age 11-12 years old.
-Most children only require two doses of the vaccine when vaccinated before age 15.
-Studies suggest that the protection provided by the HPV vaccine is long lasting. Data from patients followed for 10 years substantiates protection has remained high in those individuals. There has been no evidence of the protection decreasing over time.
-Over 120 million doses of the HPV vaccine have been distributed since the vaccine was licensed, and data continue to show the vaccine is safe and effective.
-HPV infections, genital warts, and cervical pre-cancers have dropped significantly since the vaccine has been in use in the United States.
-Studies indicate there have been reductions of HPV cases due to vaccines:
* 86% among teenage girls
* 71% among adult young women
* 40% among women
The HPV vaccine is recommended for boys and girls at 11-12 years of age but can be given as young as 9 and up to 14 years of age and in 2 doses that are 6-12 months apart. If the vaccine is given after age 15 up through the age of 26, there are 3 doses required. The vaccine is not recommended for people over the age of 26 but can be a discussion with their doctor if they were never vaccinated at a younger age to discuss their risk for contracting HPV and the possible benefits to receiving the vaccine at this time.
It is recommended to receive the vaccine at the younger age prior to becoming sexually active.
The vaccine should not be given to people that have had a prior allergic reaction to vaccines or who are pregnant.
There are 3 different vaccines but the Gardasil 9 is the one given in the United States.
As healthcare pro ...
Background & Objective: Worldwide, nearly 350 and125 million persons have chronic hepatitis B &C virus (HBV& HCV) infections, respectively. This study aimed to bridge the gap between knowledge of HBV & HCV infections and theirs prevalence among pregnant women, through assessing the impact of an educational intervention on knowledge of pregnant women toward HBV & HCV infections.
Methods: The study was a quasi-experimental one, 100 pregnant women were enrolled in the study they were in third trimester. Structured interviewing sheet, laboratory investigations, educational interventions and pre & posttest formats were utilized for the study.
Mastering Wealth: A Path to Financial FreedomFatimaMary4
### Understanding Wealth: A Comprehensive Guide
Wealth is a multifaceted concept that extends beyond mere financial assets. It encompasses a range of elements including money, investments, property, and other valuable resources. However, true wealth also includes non-material aspects such as health, relationships, and personal fulfillment. This guide delves into the various dimensions of wealth, exploring how it can be created, sustained, and enjoyed.
#### Defining Wealth
Traditionally, wealth is defined as the abundance of valuable resources or material possessions. It includes financial assets like cash, savings, stocks, bonds, and real estate. However, a broader understanding of wealth considers factors such as personal well-being, emotional health, social connections, and intellectual growth. This holistic view recognizes that true wealth is not solely about accumulating money but also about enhancing one's quality of life.
#### The Importance of Financial Wealth
Financial wealth remains a critical component of overall wealth. It provides security, freedom, and the ability to pursue opportunities. Key elements of financial wealth include:
1. **Savings**: Money set aside for future use. It is crucial for emergencies, large purchases, and financial goals.
2. **Investments**: Assets purchased with the expectation that they will generate income or appreciate over time. Common investments include stocks, bonds, mutual funds, real estate, and businesses.
3. **Income**: Regular earnings from work, investments, or other sources. Consistent income is essential for maintaining and growing wealth.
4. **Debt Management**: Effectively managing debt ensures that it does not erode financial wealth. This includes paying off high-interest debt and using credit wisely.
#### Creating Wealth
Creating wealth involves generating and accumulating financial and non-financial resources. The process can be broken down into several key strategies:
1. Education and Skill Development: Investing in education and skills enhances earning potential. Higher education, professional certifications, and continuous learning can lead to better job opportunities and higher salaries.
2. Entrepreneurship: Starting and running a successful business can be a significant source of wealth. Entrepreneurship requires innovation, risk-taking, and effective management.
3. Investing: Making smart investments is essential for wealth creation. This involves understanding different types of investments, assessing risks, and making informed decisions. Diversifying investments can reduce risk and increase potential returns.
4. Saving and Budgeting: Effective saving and budgeting help accumulate wealth over time. Setting financial goals, creating a budget, and sticking to it are foundational steps in wealth creation.
5. Real Estate: Investing in property can provide rental income and capital appreciation. Real estate is a tangible asset that can hedge against inflation
EATING DISORDERS (Psychiatry-7)by dr Shivam sharma.pptxShivam Sharma
For any queries ,contact shvmshrm@outlook.com
---
## Introduction to Eating Disorders
Welcome to this comprehensive presentation on Eating Disorders, a critical and often misunderstood area of mental health. This presentation is designed to provide in-depth knowledge and insights into the various aspects of eating disorders, making it valuable for both postgraduate medical aspirants preparing for the INI-CET and the general public seeking to understand these complex conditions.
### Objectives:
1. **Understanding Eating Disorders**: Gain a clear understanding of what eating disorders are, their types, and their distinguishing characteristics.
2. **Etiology and Risk Factors**: Explore the underlying causes and risk factors that contribute to the development of eating disorders.
3. **Clinical Features and Diagnosis**: Learn about the clinical features, diagnostic criteria, and the importance of early detection.
4. **Management and Treatment**: Review the current approaches to managing and treating eating disorders, including medical, psychological, and nutritional interventions.
5. **Prevention and Awareness**: Discuss strategies for prevention, early intervention, and increasing awareness about eating disorders.
This presentation aims to bridge the gap between academic knowledge and practical understanding, providing you with the tools to recognize, diagnose, and effectively manage eating disorders. Whether you are preparing for a medical exam or seeking to educate yourself or others about these serious conditions, this presentation will equip you with essential information and practical insights.
Let's begin our journey into understanding eating disorders and the significant impact they have on individuals and society.
---
For any queries ,contact shvmshrm@outlook.com
More Related Content
Similar to genital-herpes-screening-final-recommendation.pdf
Pequeño análisis sobre la necesidad de Vacunar y su impacto en la sociedad en...Dr. Manuel Concepción
Debo vacunar a mi hijo.doc
https://xemide-new-american-institute.tumblr.com/
https://www.youtube.com/watch?v=S1zaOUV0BTg
@newaericaninstitutexcupware
https://twitter.com/grow_follow
"Brian Shilhavy"
Dr. Andrew Moulden
https://www.amazon.com/Medical-Doctors-Opposed-Forced-Vaccinations-ebook/dp/B00YVU2K0I/ref=pd_sim_351_1
http://healthimpactnews.com/2014/gardasil-vaccine-one-more-girl-dead/
Vademecum.es
Papilomavirus (tipos humanos 6, 11, 16, 18, 31, 33, 45, 52, 58)
New england latest post.
http://www.nejm.org/medical-research/viral-infections#qs=%3Fsubtopic%3Dviral-infections%26category%3Dresearch
http://www.nejm.org/doi/full/10.1056/NEJMoa1612296
SOURCE INFORMATION
From the Department of Epidemiology Research, Statens Serum Institut, Copenhagen (N.M.S., B.P., D.M.-N., H.S., A.H.); and the Clinical Epidemiology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm (B.P.).
Address reprint requests to Dr. Scheller at the Department of Epidemiology Research, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark, or a
nims@ssi.dk.
Informacion negativa técnica.
http://www.nhs.uk/Conditions/vaccinations/Pages/hpv-vaccine-cervarix-gardasil-side-effects.aspx
HPV vaccine side effects - Vaccinations - NHS Choices
Find out the side effects of the HPV vaccine and how common they are plus how to report a vaccine side effect.
nhs.uk
http://www.nhs.uk/Conditions/vaccinations/Pages/reporting-side-effects.aspx
CDC opinion on vaccine safety
https://www.cdc.gov/vaccinesafety/research/publications/index.html
Vaccine Safety Publications Publications | Research | Vaccine Safety | CDC
Access publications on vaccine safety by specific safety system, safety topic, and year.
cdc.gov
IN SPANISH
https://www.cdc.gov/vaccines/vpd-vac/hpv/downloads/dis-HPV-color-office-sp.pdf
https://www.cdc.gov/vaccines/parents/diseases/teen/hpv-indepth-color-sp.pdf
www.cdc.gov
cdc.gov
Human PapillomavirusVaccineUSU, FNP 590 Health Promotion, EdNarcisaBrandenburg70
Human Papillomavirus
Vaccine
USU, FNP 590 Health Promotion, Education, and Disease Prevention Across the Lifespan
Our Group 2 presentation is on the Human Papilloma Virus Vaccine. We will talk about what the HPV virus is, how you contact the virus and can prevent getting the virus, some information about the vaccine which includes some pros/cons and the issues and controversy surrounding it.
1
HPV is a group of approximately 150 related viruses that can lead up to 6 different types of cancers later on in life.
HPV is the most common sexually transmitted infection.
HPV appears as skin or mucous membrane growths on the vagina, cervix, rectum, anus, penis, and scrotum.
What is Human Papilloma Virus (HPV)?
HPV is spread from skin to skin sexual contact with someone who has the virus.
HPV is the most common STD. Most people do not know they have it unless they feel or see the skin irritation and see their physician for diagnosis but the lesions usually go away on their own.
How do you get HPV?
The best way to prevent contracting HPV is to avoid sexual contact with someone who has the virus.
The HPV vaccine significantly reduces your chances of contracting the virus.
Prevention of HPV
HPV vaccination
-The vaccine is recommended for children at age 11-12 years old.
-Most children only require two doses of the vaccine when vaccinated before age 15.
-Studies suggest that the protection provided by the HPV vaccine is long lasting. Data from patients followed for 10 years substantiates protection has remained high in those individuals. There has been no evidence of the protection decreasing over time.
-Over 120 million doses of the HPV vaccine have been distributed since the vaccine was licensed, and data continue to show the vaccine is safe and effective.
-HPV infections, genital warts, and cervical pre-cancers have dropped significantly since the vaccine has been in use in the United States.
-Studies indicate there have been reductions of HPV cases due to vaccines:
* 86% among teenage girls
* 71% among adult young women
* 40% among women
The HPV vaccine is recommended for boys and girls at 11-12 years of age but can be given as young as 9 and up to 14 years of age and in 2 doses that are 6-12 months apart. If the vaccine is given after age 15 up through the age of 26, there are 3 doses required. The vaccine is not recommended for people over the age of 26 but can be a discussion with their doctor if they were never vaccinated at a younger age to discuss their risk for contracting HPV and the possible benefits to receiving the vaccine at this time.
It is recommended to receive the vaccine at the younger age prior to becoming sexually active.
The vaccine should not be given to people that have had a prior allergic reaction to vaccines or who are pregnant.
There are 3 different vaccines but the Gardasil 9 is the one given in the United States.
As healthcare pro ...
Background & Objective: Worldwide, nearly 350 and125 million persons have chronic hepatitis B &C virus (HBV& HCV) infections, respectively. This study aimed to bridge the gap between knowledge of HBV & HCV infections and theirs prevalence among pregnant women, through assessing the impact of an educational intervention on knowledge of pregnant women toward HBV & HCV infections.
Methods: The study was a quasi-experimental one, 100 pregnant women were enrolled in the study they were in third trimester. Structured interviewing sheet, laboratory investigations, educational interventions and pre & posttest formats were utilized for the study.
Mastering Wealth: A Path to Financial FreedomFatimaMary4
### Understanding Wealth: A Comprehensive Guide
Wealth is a multifaceted concept that extends beyond mere financial assets. It encompasses a range of elements including money, investments, property, and other valuable resources. However, true wealth also includes non-material aspects such as health, relationships, and personal fulfillment. This guide delves into the various dimensions of wealth, exploring how it can be created, sustained, and enjoyed.
#### Defining Wealth
Traditionally, wealth is defined as the abundance of valuable resources or material possessions. It includes financial assets like cash, savings, stocks, bonds, and real estate. However, a broader understanding of wealth considers factors such as personal well-being, emotional health, social connections, and intellectual growth. This holistic view recognizes that true wealth is not solely about accumulating money but also about enhancing one's quality of life.
#### The Importance of Financial Wealth
Financial wealth remains a critical component of overall wealth. It provides security, freedom, and the ability to pursue opportunities. Key elements of financial wealth include:
1. **Savings**: Money set aside for future use. It is crucial for emergencies, large purchases, and financial goals.
2. **Investments**: Assets purchased with the expectation that they will generate income or appreciate over time. Common investments include stocks, bonds, mutual funds, real estate, and businesses.
3. **Income**: Regular earnings from work, investments, or other sources. Consistent income is essential for maintaining and growing wealth.
4. **Debt Management**: Effectively managing debt ensures that it does not erode financial wealth. This includes paying off high-interest debt and using credit wisely.
#### Creating Wealth
Creating wealth involves generating and accumulating financial and non-financial resources. The process can be broken down into several key strategies:
1. Education and Skill Development: Investing in education and skills enhances earning potential. Higher education, professional certifications, and continuous learning can lead to better job opportunities and higher salaries.
2. Entrepreneurship: Starting and running a successful business can be a significant source of wealth. Entrepreneurship requires innovation, risk-taking, and effective management.
3. Investing: Making smart investments is essential for wealth creation. This involves understanding different types of investments, assessing risks, and making informed decisions. Diversifying investments can reduce risk and increase potential returns.
4. Saving and Budgeting: Effective saving and budgeting help accumulate wealth over time. Setting financial goals, creating a budget, and sticking to it are foundational steps in wealth creation.
5. Real Estate: Investing in property can provide rental income and capital appreciation. Real estate is a tangible asset that can hedge against inflation
EATING DISORDERS (Psychiatry-7)by dr Shivam sharma.pptxShivam Sharma
For any queries ,contact shvmshrm@outlook.com
---
## Introduction to Eating Disorders
Welcome to this comprehensive presentation on Eating Disorders, a critical and often misunderstood area of mental health. This presentation is designed to provide in-depth knowledge and insights into the various aspects of eating disorders, making it valuable for both postgraduate medical aspirants preparing for the INI-CET and the general public seeking to understand these complex conditions.
### Objectives:
1. **Understanding Eating Disorders**: Gain a clear understanding of what eating disorders are, their types, and their distinguishing characteristics.
2. **Etiology and Risk Factors**: Explore the underlying causes and risk factors that contribute to the development of eating disorders.
3. **Clinical Features and Diagnosis**: Learn about the clinical features, diagnostic criteria, and the importance of early detection.
4. **Management and Treatment**: Review the current approaches to managing and treating eating disorders, including medical, psychological, and nutritional interventions.
5. **Prevention and Awareness**: Discuss strategies for prevention, early intervention, and increasing awareness about eating disorders.
This presentation aims to bridge the gap between academic knowledge and practical understanding, providing you with the tools to recognize, diagnose, and effectively manage eating disorders. Whether you are preparing for a medical exam or seeking to educate yourself or others about these serious conditions, this presentation will equip you with essential information and practical insights.
Let's begin our journey into understanding eating disorders and the significant impact they have on individuals and society.
---
For any queries ,contact shvmshrm@outlook.com
TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...kevinkariuki227
TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn Hockenberry, Cheryl Rodgers, Verified Chapters 1 - 31, Complete Newest Version.pdf
TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn Hockenberry, Cheryl Rodgers, Verified Chapters 1 - 31, Complete Newest Version.pdf
TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...kevinkariuki227
TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Edition Schlenker & Gilbert, Verified Chapters 1 - 25, Complete Newest Version.pdf
TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Edition Schlenker & Gilbert, Verified Chapters 1 - 25, Complete Newest Version.pdf
TEST BANK For Timby's Introductory Medical-Surgical Nursing, 13th American Ed...kevinkariuki227
TEST BANK For Timby's Introductory Medical-Surgical Nursing, 13th American Edition by Donnelly-Moreno, Verified Chapters 1 - 72, Complete Newest Version.pdf
TEST BANK For Timby's Introductory Medical-Surgical Nursing, 13th American Edition by Donnelly-Moreno, Verified Chapters 1 - 72, Complete Newest Version.pdf
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection